Loading
Skip Navigation LinksHome » Articles » Women’s health

ملخص

تعد اضطرابات الدورة الشهرية من أهم الأعراض المصاحبة لمتلازمة ما قبل الطمث (PMS)، التي تتسبب في اضطرابات موهنة في كثير من الأحيان. ولا تزال أسباب الإصابة بهذا المتلازمة غير واضحة المعالم، كما أن معظم الأساليب المستخدمة لعلاجها لم تثبت قدرًا مقنعًا من الفعالية. ومع ذلك، هناك قدر لا بأس به من المؤلفات الطبية الحالية التي تشير إلى ممارسة النشاط البدني بانتظام باعتبارها وسيلة فعالة لعلاج أو القضاء على الأعراض البدنية والنفسية لمتلازمة ما قبل الطمث بدرجة كبيرة.

وفي الوقت ذاته، أثبتت ممارسة التمارين بشكل عنيف ومستمر قدرة على الحد من الأعراض المرتبطة بالتميّؤ (مثل الانتفاخات وألم العضلات) والأعراض العاطفية (مثل الاكتئاب والقلق)، وذلك عن طريق قيامها "بتعديل" جهاز الغدد الصماء. وتعد متلازمة ما قبل الطمث اضطرابًا معقدًا لا يزال يكتنفه الكثير من الغموض وسوء الفهم نتيجة للأسباب المتغيرة والمتداخلة على نحو معقد.

وإضافة إلى الفوائد الصحية التي يمكن الحصول عليها بشكل عام نتيجة لتبني أنماط الحياة النشطة، فإن ممارسة التمارين تساعد كذلك في الحد من الأعراض المرتبطة بالتميؤ، وتحفيف حدة القلق والاكتئاب، وتحسن المظهر الجسدي للسيدات اللاتي تعانين من متلازمة ما قبل الطمث، فضلاً عن إمكانية ممارستها بطرق وأساليب مختلفة (مثل ركوب الدراجات والهرولة، والسباحة، ونحوها) وبدرجة شدة متباينة (كالشدة المتوسطة أو العالية). وعلى الرغم من أن النشاط البدني لا يعد علاجًا شافيًا لجميع أشكال متلازمة ما قبل الطمث، إلا أن البراهين التراكمية تشير أنه يعد سلاحًا فعالاً ضمن ترسانة العلاج المتوفرة لدى الممارسين.

Women’s health

Exercise as a therapeutic modality for the treatment of women with premenstrual syndrome

 

– Written by Khalid W. Al-Bibi, Qatar

 

Millions of women are affected by premenstrual syndrome (PMS) during part or all of their reproductive years. PMS is the name given to the group of cyclic affective, somatic and behavioural symptoms that reoccur during the 10 days prior to menstruation (luteal phase), with symptoms disappearing with the onset of menstruation or soon thereafter1. PMS symptoms can significantly interfere with the physiological, psychological and social function of afflicted women. The severe and predominantly psychological form of PMS is termed ‘premenstrual dysphoric disorder’ (PMDD). The key diagnostic feature for PMS is that the symptoms must be absent between the end of menstruation and ovulation2.

 

Although there are approximately 200 symptoms that have been associated with PMS, there are no symptoms that are unique to and diagnostic of PMS. Diagnosis of PMS depends on the temporal relationship between the symptoms and the days of menstruation. Diagnosing PMS is further complicated by the fact that some affective, behavioural and physical symptoms are not specific to PMS. For example, 40 to 60% of women who present for treatment for what they think is PMS were found to have generalised psychiatric or affective disorders3,4. Therefore, it is important to distinguish PMS from concomitant medical or psychiatric disorders. A means for detecting chronic psychiatric disorders is the absence of at least one asymptomatic week in the mid-follicular phase of every menstrual cycle1. Given that retrospective recall is poor, the symptoms must be ascertained by prospective monitoring. Smith and Schiff5 and Mortola6 recommend that a preliminary diagnosis of PMS may be made from the prospective daily ratings of one menstrual cycle, but that a monitoring period of two menstrual cycles be used to confirm the diagnosis.

 

Globally, PMS has been reported to affect as many as 24 to 87% of all females for varying durations at some point in their reproductive years7-12. The large range in the reported prevalence is due to a number of methodological issues in the research. As such, interpretation of the published literature must be made in consideration of the following potential but serious limitations:

  • Before 1989, there were no uniformly accepted diagnostic criteria or a standard working definition of the disorder, often leading to poor communication between researchers and clinicians13.
  • Samples in the published literature often included non-PMS research participants such as peri-menopausal women, pre-adolescent girls and other participants suffering from non-PMS psychiatric disorders.
  • In the literature, there has been a working assumption that the disorder constituted one syndrome rather than multiple groupings of different ones14.
  • The literature has often lacked research controls for socialising agents such as cultural and religious bias.
  • Invalid and unreliable tools used to assess PMS symptoms have been present in the research.
  • The literature has used weak research designs and/or improper statistical analyses.
  • The literature has used retrospective evaluation methods.
  • The literature suffers from missing physical and/or anthropometric data. The American College of Obstetrics and Gynecology states that 20 to 40% of all women experience PMS symptoms that are sufficiently severe to affect their lifestyle or work and that 3 to 8% meet the strict criteria for PMDD8,15. Even at their most conservative, PMS estimates highlight a health issue that warrants serious attention.

 

PREVALENCE OF PMS IN THE MENA REGION

Data on the prevalence of PMS in the Middle East and North Africa (MENA) was late in appearing in the literature. In 1990, Al-Gasseer16 measured the prevalence of PMS in 172 Bahraini women (aged 17 to 45  years) at 30%. A 1992 study on 342 Egyptian women revealed PMS frequency ranged from 36% for breast pain/tenderness to 66% for stomach and back cramps17. A study conducted on 488 college students at King Faisal University in Dammam, Saudi Arabia, rated the prevalence of ‘high-severity’ PMS at 37.5%18. A study published 3 years later in 2006 by Rizk et al19, rated the prevalence of PMS in 12 to 18-year-old Emirati girls at 16.4%. A 2012 study conducted in Iran on 602 females aged 14 to 19 years estimated the prevalence of PMS at 37.2%20.

 

SYMPTOMS AND TEMPORAL PATTERNS

Since 1931, over 200 symptoms have been attributed to PMS2. Table 1 lists 40 of the most commonly reported symptoms. Reid and Yen21 state that the appearance of PMS symptoms in women with a pure PMS symptomatology seem to differ with respect to the manifestation of the symptom(s) to menses. Four patterns of PMS-symptom timing have been observed:

  1. In the first pattern, symptoms gradually increase in severity throughout the luteal phase and end with the onset of menses.
  2. In the second pattern, symptoms gradually increase throughout the luteal phase but persist into the first few days of the next cycle.
  3. Women who demonstrate the third pattern experience severe symptoms that are limited only to a few days in the late-luteal phase.
  4. Women who demonstrate the fourth pattern experience two periods of severe symptoms, the first around the time of ovulation and the second immediately prior to menses.

 

PMS-SYMPTOM SUBGROUPS

Early research by Moos et al22 conducted on 579 women in 1969 enabled the categorisation of 47 common PMS symptoms into more clinically manageable subgroups. Eight PMS subgroups were derived in this early study:

  1. pain
  2. concentration
  3. behavioural change
  4. autonomic reactions
  5. water retention
  6. negative affect
  7. arousal
  8. motor-control.

 

Most PMS questionnaires in use today include stems from each of the above subgroups12,23. Later research by Bibi (conducted in 1995) derived four primary subgroups14. Upon factor analysis of 21 PMS symptoms, measured prospectively over four menstrual cycles, results revealed the clustering of the symptoms into four main PMS subgroups: H, D, A and F (Table 2). Other similar subgroupings have been offered in the literature.

 

PMS THERAPIES: FROM PLACEBO TO BI-ZARRE

Dr RT Frank24 first described PMS in 1931 as a unique disorder requiring therapeutic attention. He described the disorder as “a feeling of indescribable tension from 10 to 7 days preceding menstruation which, in most instances, continues until the time that the menstrual flow occurs. Their personal suffering is intense and manifests itself in many reckless and sometimes reprehensible actions.” Dr Frank’s early description highlights both the severity of the symptoms as well as the desperation of the afflicted women in their attempt to seek a cure or at least relief from the symptoms. To date, the tried methods include hormone therapy, yoga, vitamin and mineral supplementation, psychological counselling, hypnosis, meditation, self-hypnosis, biofeedback, guided-imagery treatment, phototherapy (exposure to sunlight) and surgery. Unfortunately, these treatments have shown limited success in  reducing PMS symptomatology. Evidence on the efficacy of hormonal treatment aimed at the suppression of ovulation or at reducing progesterone sensitivity has been mixed or fraught with undesirable consequences such as masculinising or menopausal side-effects25,26. Pharmaceutical therapy such as anti-depressants should not be avoided when indicated. However, when drug side-effects tip the risk-to-benefit ratio against the patient, alternative methods (in lieu of or in conjunction with medication) must be sought.

 

EXERCISE AND MENTAL HEALTH

The increasing interest in exercise research over the past 4 decades has enforced the belief that physical fitness has psychological as well as physiological benefits. Due to the multitude of people who have reported that they ‘feel better’ when they exercise, psychologists and psychiatrists in the late 1970s began using aerobic exercise as a means of alleviating a host of anxiety- and depression-related disorders that were not responding well to medications. As anecdotal reports of the benefits of exercise peaked in the 1980s, many mental-health practitioners became interested in prescribing exercise for their patients as standard practice.

 

Several hypotheses that attempt to explain the positive relationship between exercise and improved mental health have been offered. One hypothesis, which discounts any physiological connection, is termed the ‘distraction theory’. This theory states that the distraction from stressful stimuli associated with exercise is responsible for the improved affect rather than the physical conditioning. A second hypothesis is termed the ‘monoamine hypothesis’. This hypothesis states that neurotransmitters such as noradrenaline, serotonin and γ-Aminobutyric acid are associated with depression27. A third hypothesis is termed the ‘endorphin hypothesis’. This popular hypothesis states that exercise can increase the brain’s  production of endorphins leading to a narcotic feeling and/or a state of euphoria.

 

Anxiety and depression reduction following acute28,29 and chronic30-35 exercise has been well documented and acute physical activity has been found to cause a reduction in anxiety for a period that may last up to 5 hours following a bout of exercise34,36. In 1984, the National Institute of Mental Health conducted a workshop on exercise and mental health32. The workshop yielded the following consensus statements:

  • Physical fitness is positively associated with mental health and well-being.
  • Exercise is associated with the reduction of stress emotions such as state anxiety.
  • Anxiety and depression are common symptoms of failure to cope with mental stress and exercise has been associated with a decreased level of mild-to-moderate depression and anxiety.
  • Long-term exercise is usually associated with reductions in traits such as neuroticism and anxiety.
  • Severe depression usually requires professional treatment, which may include medication, electroconvulsive therapy and/or psychotherapy, with exercise as an adjunct.
  • Appropriate exercise results in reductions in various stress indices such as neuromuscular tension, resting heart rate and some stress hormones.
  • Current clinical opinion holds that exercise has beneficial emotional effects across all ages and in both genders.
  • Physically healthy people who require psychotropic medication may safely exercise when exercise and medications are titrated under close medical supervision.

 

EXERCISE AS MEDICINE FOR PMS AND PMDD

The concept that the menstrual cycle is altered by exercise was initially suggested by in 1939 by Selye37 and later supported by many researchers14,38-47. Exercise has been proposed as a significant potential therapeutic modality for PMS and PMDD  because evidence suggests that exercise can reduce stress, improve depressive symptoms in chronically depressed individuals, as  well as elevate mood states in normal subjects via central effects on endogenous  opiates28,32-35,48-52. A recent study conducted  on 16 to 20-year-old Egyptian girls arrived at the same conclusion, demonstrating positive diminution of PMS symptoms on all subscale symptoms as well as many blood  markers, including a decrease in prolactin, estradiol and progesterone levels53. A similar study conducted in Iran on 40 female college students yielded the same results40.

 

CONCLUSION

PMS is a complex, multifactorial, cyclical outcome that is affected by physiological factors, as well as many others including social, cultural, surgical and genetic. This disorder afflicts many women during part or all of their reproductive years and can be severely debilitating. Unfortunately, reliable treatment has been as elusive as the syndrome is complex. The prevalence of PMS in the MENA region has been shown to be similar to its prevalence in the Western world and therefore, this issue is worthy of serious consideration by primary-care and obstetric and gynaecologic physicians, as well as other healthcare practitioners in this region. All evidence suggests that exercise is effective in the reduction or elimination of some PMS symptoms, particularly the physical and psychological symptoms. Patients with unresolved conditions should consider seeking advice from reproductive endocrinologists and PMS experts.

 

References

  1. Halbreich U, Endicott J. Relationship of dysphoric premenstrual changes to depressive disorders. Acta Psychiatr Scand 1985; 71:331-338.
  2. Halbreich U, Endicott J, Lesser J. The clinical diagnosis and classification of premenstrual changes. Can J Psychiatry 1985; 30:489-497.
  3. Endicott J, Halbreich U, Schacht S, Nee J. Premenstrual Changes and Affective Disorders. Psychosom Med 1981; 43:519-529.
  4. Yuk VJ, Jugdutt AV, Cumming CE, Fox EE, Cumming DC. Towards a definition of PMS: a factor analytic evaluation of premenstrual change in non-complaining women. J Psychosom Res 1990; 34:439-446.
  5. Smith S, Schiff I. The premenstrual syndrome--diagnosis and management. Fertil Steril 1989; 52:527-543.
  6. Mortola JF. Issues in the diagnosis and research of premenstrual syndrome. Clin Obstet Gynecol 1992; 35:587-598.
  7. Logue CM, Moos RH. Perimenstrual symptoms: prevalence and risk factors. Psychosom Med 1986; 48:388-414.
  8. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28:1-23.
  9. Johnson SR, McChesney C, Bean J. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med 1988; 33:340-346.
  10. Monagle L, Dan A, Krogh V, Jossa F, Fannaro E, Trevisan M. Perimenstrual symptom prevalence rates: an Italian-American comparison. Am J Epidemiol 1993; 138:1070-1081.
  11. Praschak-Rieder N, Willeit M, Neumeister A, Hilger E, Stastny J, Thierry N et al. Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. J Affect Disord 2001; 63:239-42.
  12. Steiner M, Peer M, Palova E, Freeman EW, Macdougall M, Soares CN. The Premenstrual Symptoms Screening Tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Arch Womens Ment Health 2011; 14:77-81.
  13. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978; 35:773-782.
  14. Bibi KW. The effects of aerobic exercise on premenstrual syndrome symptoms. Ph.D. thesis. University of Connecticut. 1995.
  15. Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, Skouby SO, Smith L et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 2012; 85:437-445.
  16. Al-Gasseer NH. Experience of menstrual symptoms among Bahraini women. Ph.D. thesis. University of Illinois at Chicago. 1990.
  17. Khella A. Epidemiologic study of premenstrual symptoms. J Egypt Public Health Assoc 1992; 67:109-118.
  18. Rasheed P, Sowailem L. Prevalence and predictors of premenstrual syndrome among college-aged women in Saudi Arabia. Ann Saudi Med 2003; 23:381-287.
  19. Rizk DE, Mosallam M, Alyan S, Nagelkerke N. Prevalence and impact of premenstrual syndrome in adolescent schoolgirls in the United Arab Emirates. Acta oObstet Gynecol Scand 2006; 85:589-598.
  20. Delara M, Ghofranipour F, Azadfallah P, Tavafian SS, Kazemnejad A, Montazeri A. Health related quality of life among adolescents with premenstrual disorders: a cross sectional study. Health Qual Life Outcomes 2012;10:1.
  21. Reid RL, Yen S. The premenstrual syndrome. Clin Obstet Gynecol 1983; 26:710-718.
  22. Moos RH, Kopell BS, Melges FT, Yalom ID, Lunde DT, Clayton RB et al. Fluctuations in symptoms and moods during the menstrual cycle. J Psychosom Res. 1969; 13:37-44.
  23. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Archives of Women’s Mental Health 2003; 6:203-209.
  24. Frank RT. The hormonal causes of premenstrual tension. Arch Neur Psych 1931; 26:1053-1057.
  25. Samadi Z, Taghian F, Valiani M. The effects of 8 weeks of regular aerobic exercise on the symptoms of premenstrual syndrome in non-athlete girls. Iran J Nurs Midwifery Res 2013; 18:14-19.
  26. Sarno AP Jr, Miller EJ Jr, Lundblad EG. Premenstrual syndrome: beneficial effects of periodic, low-dose danazol. Obstet Gynecol 1987; 70:33-36.
  27. Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry 1996; 153:718-720.
  28. Morgan WP, Roberts JA, Brand FR, Feinerman AD. Psychological effect of chronic physical activity. Med Sci Sports 1970; 2:213-217.
  29. Roth DL. Acute emotional and psychophysiological effects of aerobic exercise. Psychophysiology 1989; 26:593-602.
  30. Fremont J, Craighead LW. Aerobic exercise and cognitive therapy in the treatment of dysphoric moods. Cognit Ther Res 1987; 11:241-251.
  31. Goldwater BC, Collis ML. Psychologic effects of cardiovascular conditioning: A controlled experiment. Psychosom Med 1985; 47:174-181.
  32. Morgan WP. Affective beneficence of vigorous physical activity. Med Sci Sports Exerc 1985; 17:94-100.
  33. Cameron OG, Hudson CJ. Influence of exercise on anxiety level in patients with anxiety disorders. Psychosomatics 1986; 27:720-723.
  34. Doyne EJ, Ossip-Klein DJ, Bowman ED, Osborn KM, McDougall-Wilson IB, Neimeyer RA. Running versus weight lifting in the treatment of depression. J Consult Clin Psychol 1987; 55:748-754.
  35. deVries HA, Wiswell RA, Bulbulian R, Moritani T. Tranquilizer effect of exercise. Acute effects of moderate aerobic exercise on spinal reflex activation level. Am J Phys Med 1981; 60:57-66.
  36. Raglin JS, Morgan WP. Influence of exercise and quiet rest on state anxiety and blood pressure. Med Sci SPorts Exerc 1987; 19:456-463.
  37. Selye H. The effect of adaptation to various damaging agents on the female sex organs in the rat. Endocrinology 1939; 25:615-624.
  38. Aganoff JA, Boyle GJ. Aerobic exercise, mood states and menstrual cycle symptoms. J Psychosom Res 1994; 38:183-192.
  39. Bullen BA, Skrinar GS, Beitins IZ, von Mering G, Turnbull BA, McArthur JW. Induction of menstrual disorders by strenuous exercise in untrained women. N Engl J Med 1985; 312:1349-1353.
  40. De Souza MJ, Maresh CM, Maguire MS, Kraemer W, Flora-Ginter G, Goetz K. Menstrual status and plasma vasopressin, renin activity, and aldosterone exercise responses. J Appl Physiol 1989; 67:736-743.
  41. Gamberale F, Strindberg L, Wahlberg I. Female work capacity during the menstrual cycle: physiological and psychological reactions. Scand J Work Environ Health 1975; 1:120-127.
  42. Garlick M, Bernauer E. Exercise during the menstrual cycle: variations in physiological baselines. Res Q 1968; 39:533-542.
  43. Keizer HA, Rogol AD. Physical exercise and menstrual cycle alterations. What are the mechanisms? Sports Med 1990; 10:218-235.
  44. Prior J, Vigna Y, Alojada N. Conditioning exercise decreases premenstrual symptoms. A prospective controlled three month trial. Eur J App Physiol Occup Physiol 1986; 55:349-355.
  45. Prior J, Vigna Y, Sciarretta D, Alojado N, Schulzer M. Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. Fertil Steril 1987; 47:402-408.
  46. Stephenson L, Kolka MA, Wilkerson J. Perceived exertion and anaerobic threshold during the menstrual cycle. Med Sci Sports Exerc 1982; 14:218-222.
  47. Walberg-Rankin J, Franke W, Gwazdauskas F. Response of beta-endorphin and estradiol to resistance exercise in females during energy balance and energy restriction. Int J Sports Med 1992; 13:542-547.
  48. Blumenthal JA, Williams SR, Needels TL, Wallace AG. Psychological changes accompany aerobic exercise in healthy middle-aged adults. Psychosom Med 1982; 44:529-536.
  49. Kirkcaldy BD, Shephard RJ, Siefen RG. The relationship between physical activity and self-image and problem behaviour among adolescents. Soc Psychiatry Psychiatr Epidemiol 2002; 37:544-550.
  50. Metheny WP, Smith RP. The relationship among exercise, stress, and primary dysmenorrhea. J Behav Med 1989; 12:569-586.
  51. Markoff RA, Ryan P, Young T. Endorphins and mood changes in long-distance running. Med Sci Sports Exerc 1982; 14:11-15.
  52. Roth DL, Holmes DS. Influence of physical fitness in determining the impact of stressful life events on physical and psychologic health. Psychosom Med 1985; 47:164-173.
  53. El-Lithy A, El-Mazny A, Sabbour A, El-Deeb A. Effect of aerobic exercise on premenstrual symptoms, haematological and hormonal parameters in young women. J Obstet Gynaecol 2015; 35:389-392.

 

 

 

Khalid W. Al-Bibi M.D., Ph.D.

Associate Dean for Academic Programmes

Georgetown University – Qatar

Doha, Qatar

 

Contact: kwb29@georgetown.edu

 

Image by Peter Miller

Tags :
Switch Language: list thumbnails
Bookmark and Share

Category

Healthy Lifestyle

Article Images

Copyright © Aspetar Sports Medicine Journal 2019